<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989778</url>
  </required_header>
  <id_info>
    <org_study_id>124</org_study_id>
    <nct_id>NCT03989778</nct_id>
  </id_info>
  <brief_title>Vitamin D and Polycystic Ovarian Syndrome</brief_title>
  <official_title>Efficacy of Vitamin D Supplementation and Metformin Compared to Metformin Alone for Improvement in Follicle Size of Infertile Females With Polycystic Ovary Syndrome: a Randomized Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and&#xD;
      serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen&#xD;
      Index) levels compared metformin alone in infertile Poly cystic ovarian females of&#xD;
      reproductive age group.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To measure change in endometrial thickness/number of follicles and follicular size by day 12&#xD;
      trans-vaginal ultrasound in the intervention group i.e. combination of metformin and vitamin&#xD;
      D supplementation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) as defined by &quot;the presence of any two out of three criteria&#xD;
      i.e. Oligo and/or anovulation, excess androgen activity and/or polycystic ovarian morphology&#xD;
      on ultrasound&quot;, is a prevalent cause of female infertility. In the endocrine milieu of PCOS&#xD;
      higher levels of insulin due to insulin resistance (IR) exert direct effects on the ovaries,&#xD;
      release insulin-like growth factor 1 (IGF-1) from the liver and both then increase levels of&#xD;
      testosterone. The resultant prevents the growth of ovarian follicles to acquire the required&#xD;
      dimension for ovulation (i.e. &gt; 10 mm) hence leading to anovulation and therefore&#xD;
      subfertility. Vitamin D (VD) has found to be predominantly deficient in PCOS females,&#xD;
      documented to cause IR giving rise to anovulatory cycles, hyperandrogenism and other&#xD;
      significant features of PCOS. Therefore, we have hypothesized that treatment with VD in PCOS&#xD;
      females can reduce IR, improve ovulation and signs of hyperandrogenism. Since Metformin is&#xD;
      frequently prescribed for reducing IR and hence the treatment for anovulatory infertility in&#xD;
      these females, we have planned to conduct an open label randomized control trial in PCOS&#xD;
      infertile females who have vitamin D levels &lt; than 25 ng/ml and are receiving Metformin&#xD;
      therapy after ethical approval from Aga Khan University. The intervention group will receive&#xD;
      VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once&#xD;
      every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician&#xD;
      whereas control group will receive Metformin treatment during the study period. We will&#xD;
      compare change in number of dominant follicles (more than 10 mm) / endometrial thickness in&#xD;
      both groups by Day 12 trans-vaginal ultrasound at the time of enrollment with scans done&#xD;
      after 12 and 24 weeks. The other biochemical parameters [Total Testosterone, Steroid Hormone&#xD;
      Binding Globulin, Free Androgen Index, Lipid accumulation product LAP , serum Insulin, C&#xD;
      Reactive Protein (hs-CRP) Serum Triglycerides, serum calcium and albumin] will be done at the&#xD;
      time of recruitment in both the intervention and control groups and compared&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Infertile females with Polycystic Ovarian Syndrome</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Insulin levels</measure>
    <time_frame>24 weeks</time_frame>
    <description>Decrease in insulin levels 60%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>• serum androgen levels</measure>
    <time_frame>24 weeks</time_frame>
    <description>Decrease in Serum Androgen levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase in endometrial thickness to 2mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Accumulation Product</measure>
    <time_frame>24 weeks</time_frame>
    <description>reduction in LAP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Infertility</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>he intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group will receive Metformin treatment during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D supplementation</description>
    <arm_group_label>Vitamin D supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females with age range 18- 36 years, from all ethnic background having primary&#xD;
             infertility with diagnosis of PCOS when at least 2 of these 3 elements are present:&#xD;
             hyperandrogenism, chronic anovulation and polycystic ovaries and Vitamin D deficiency&#xD;
             serum levels &lt; 25 nmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        exclusion criteria at baseline will be excluded from the study&#xD;
&#xD;
          -  Females with secondary Infertility&#xD;
&#xD;
          -  Hypercalcemia (plasma calcium concentrations&gt; 2.65 mmol/L)&#xD;
&#xD;
          -  Exclude women with Tuberculosis or other granulomatous disorders.&#xD;
&#xD;
          -  Women receiving vitamin D replacement, oral contraceptives, hormonal replacement&#xD;
             therapy, glucocorticoids, calcium supplementation, insulin-sensitizing drugs(incretin&#xD;
             mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs&#xD;
             affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids,&#xD;
             beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics,&#xD;
             anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers,&#xD;
             immunosuppressants, chemotherapeutic agents, antimicrobials (Rifampicin, isoniazid,&#xD;
             hydroqychloroquin) or any other drug modifying lipid metabolism in the previous 3&#xD;
             months prior to study&#xD;
&#xD;
          -  Women with congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting&#xD;
             tumors, type 2 diabetes mellitus, renal, hepatic or thyroid disorders,&#xD;
             hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease Hepatic failure,&#xD;
             cystic fibrosis, vaginal bleeding of unknown etiology Women Those who had Bariatric&#xD;
             surgery will also be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rehana K Rehman, PhD</last_name>
    <phone>00922134864460</phone>
    <phone_ext>4460</phone_ext>
    <email>drrehana7@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University</investigator_affiliation>
    <investigator_full_name>Rehana Rehman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

